Spoken Alpha
Autolus Therapeutics plc
Autolus Therapeutics develops and manufactures genetically engineered T cell therapies for cancer and autoimmune diseases using proprietary programming technologies.
Autolus Therapeutics plc is a Healthcare company operating in Biotechnology with a $503.0M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 10, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for AUTL.
$ curl https://api.spokenalpha.com/v1/companies/AUTLFAQ
Spoken Alpha indexes AUTL's earnings call transcripts at https://spokenalpha.com/companies/AUTL. Each call links to attributed speakers and parsed analyst Q&A.
Autolus Therapeutics plc (AUTL) held its most recent earnings call on 2026-08-11, covering fiscal Q2 2026.
Autolus Therapeutics plc (AUTL) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-10 | — | $-0.20 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-10 | $-0.15 | $-0.21 | +28.6% | $45.7M | — | — | EODHD |
| Q1 FY2026 | 2026-05-13 | $-0.27 | $-0.26 | -3.9% | $26.2M | — | — | EODHD |
| Q4 FY2025 | 2026-03-09 | $-0.34 | $-0.25 | -35.7% | $24.3M | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.30 | $-0.23 | -30.4% | $21.2M | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.18 | $-0.23 | +21.7% | $20.9M | — | — | EODHD |
| Q1 FY2025 | 2025-05-07 | $-0.26 | $-0.26 | 0.0% | $9.0M | — | — | EODHD |
| Q4 FY2024 | 2025-03-19 | $-0.09 | $-0.24 | +62.5% | $29.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.31 | $-0.22 | -40.9% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-0.22 | $-0.21 | -4.8% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-16 | $-0.24 | $-0.14 | -71.4% | $10.1M | — | — | EODHD |
| Q4 FY2023 | 2024-03-13 | $-0.45 | $-0.25 | -80.0% | $1.8M | — | — | EODHD |
| Q3 FY2023 | 2023-11-01 | $-0.26 | $-0.25 | -4.0% | $406.0K | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $-0.26 | $-0.22 | -18.2% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $-0.23 | $-0.27 | +14.8% | $1.3M | — | — | EODHD |
| Q4 FY2022 | 2023-03-06 | $-0.23 | $-0.27 | +14.8% | $3.8M | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-0.47 | $-0.46 | -2.2% | $2.4M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $-0.46 | $-0.33 | -39.4% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $-0.41 | $-0.49 | +16.3% | $166.0K | — | — | EODHD |
| Q4 FY2021 | 2022-03-09 | $-0.51 | $-0.46 | -10.9% | $180.0K | — | — | EODHD |
Source: EODHD. AUTL reported actuals as published; sparse fields render as —.